Plasma concentration of Ropivacain and Ketorolac after local infiltration during surgery in hip replacement during the first 24 postoperative hours.
- Conditions
- MedDRA version: 9.1Level: LLTClassification code 10044088Term: Total hip replacementPostoperative pain after surgery for hip replacement.
- Registration Number
- EUCTR2008-005471-10-SE
- Lead Sponsor
- ina Olofsson
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Adult males or females ASA 1-3 undergoing spinal anesthesia for elective hip replacement. After signed informed consent.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Allergy for NSAID or local anesthetic, psychiatric disorder, demens, AV-block III, cardiac disorders, ulcus ventriculi and duodeni, renal disorders, coagulation disorder and patients who refuses to participate.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: Plasmaconcentration of ropivacain (Narop) and ketorolac (Toradol) and its pharmacokinetict the first 24 hours after surgery for hip replacement;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method